Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Pharmaceuticals

Market Closed - NSE India S.E. 05:17:54 21/06/2024 pm IST 5-day change 1st Jan Change
2,166 INR -1.35% Intraday chart for Mankind Pharma Limited -3.31% +9.27%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Mankind Pharma Limited Receives Order from Office of Superintendent of Central Tax, Bholakpur, Telangana CI
Advent International Receives 6-7 Bids for Bharat Serums CI
Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024
Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4 MT
India's Mankind Pharma's Q4 profit jumps on strength in chronic drugs segment RE
Mankind Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
India's weight in key MSCI equity index hits another high, to boost inflows RE
Mankind Pharma Reportedly in Fray to Acquire Advent's Stake in Bharat Serums CI
Mankind Pharma Limited Receives Order from Office of the Assistant Commissioner of Central Tax, Ballygunge Division Kolkata CI
KKR, Novo Nordisk, Others Reportedly Bid for Healthium Buy CI
Mankind Pharma Limited Receives Order from Office of Commissioner of Central Tax, Central Excise and Service Tax, Secunderabad GST Commissionerate GST Bhawan, Hyderabad CI
CARE Gives AA+ Rating to Mankind Pharma's Long-term Bank Financing; Outlook Stable MT
Mankind Pharma to Sell its Over the Counter Business on Slump Sale Basis CI
Mankind Pharma to Sell OTC Business to Wholly-Owned Subsidiary MT
Mankind Pharma to Form New Subsidiary for Consumer Healthcare Products MT
Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary Mankind Consumer Products Private Limited CI
Mankind Reportedly Joins Race for Healthium Medtech CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India CI
India's Jubilant Pharmova posts quarterly profit RE
Transcript : Mankind Pharma Limited, Q3 2024 Earnings Call, Feb 02, 2024
Mankind Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit; Shares Rise 3% MT
India's Mankind Pharma beats Q3 profit estimates on strong demand RE
Mankind Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
India's IPO momentum seen growing on prospects of political stability RE
Chart Mankind Pharma Limited
More charts
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
2,166 INR
Average target price
2,303 INR
Spread / Average Target
+6.30%
Consensus
  1. Stock Market
  2. Equities
  3. MANKIND Stock
  4. News Mankind Pharma Limited
  5. Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4